Shattuck Labs Q3 net loss more than doubles to $25.2 million

PUBT · 21h ago
Shattuck Labs Q3 net loss more than doubles to $25.2 million
  • Shattuck Labs’ third-quarter 2026 net loss more than doubled year over year to $25.2 million.
  • Research and development expenses more than doubled year over year to $21.6 million.
  • Cash, cash equivalents and short-term investments totaled $196.3 million at September 30, 2026, with operations expected to be funded into 2029.
  • The Phase 2b SL-325 Crohn’s disease trial began, with 12-week induction data expected in the first half of 2028.
  • The SL-325 hidradenitis suppurativa Phase 2 trial is expected to begin in fourth-quarter 2026, with data anticipated in first-half 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050800PRIMZONEFULLFEED9870907) on November 05, 2026, and is solely responsible for the information contained therein.